Topical resiquimod effective for early-stage cutaneous T-cell lymphoma
Topical resiquimod was effective and well tolerated in patients with early-stage cutaneous T-cell lymphoma (CTCL), in some cases inducing regression in both treated and untreated lesions, according to researchers. The mean number of prior unsuccessful therapies among the patients was 6, yet the... (Source: Skin and Allergy News)
Source: Skin and Allergy News - September 24, 2015 Category: Dermatology Source Type: news

Medical News Today: Topical drug leads to complete remission for some patients with rare skin lymphoma
Researchers reveal how a topical drug called resiquimod led to total remission for some patients with a cutaneous T cell lymphoma - a rare skin lymphoma. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 7, 2015 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Topical gel proves safe, effective treatment for patients with skin t cell lymphoma
Results of a phase one trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early stage cutaneous T cell lymphoma (CTCL) – a rare type of non-Hodgkin lymphoma that affects the skin. Currently, there is no cure for CTCL aside from a bone marrow transplant. However, the new study shows that the topical gel can eliminate malignant T cells, leading to diminished lesions. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 6, 2015 Category: Science Source Type: news

Naloxone lotion improves disabling itch in CTCL
VANCOUVER, B.C. – Naloxone lotion appears to be a safe and effective treatment for the severe chronic itching that occurs in most patients with cutaneous T-cell lymphoma, Dr. Madeleine Duvic reported at the World Congress of Dermatology. A major unmet need exists for better treatments for...googletag.display('div-gpt-ad-cta'); (Source: Skin and Allergy News)
Source: Skin and Allergy News - July 2, 2015 Category: Dermatology Source Type: news

Your NEJM Group Today: Cutaneous T-Cell Lymphoma, Sunscreen Use, Washington State IM Opportunity (FREE)
By the Editors NEJM Group offers so many valuable resources for practicing clinicians. Here's what we chose for you today: … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 23, 2015 Category: Primary Care Source Type: news

Check sweat glands, hair follicles in mycosis fungoides
SAN FRANCISCO – Check for syringotropism and folliculotropism in biopsies when managing mycosis fungoides, based on data from an ongoing observational, prospective study at Thomas Jefferson University in Philadelphia. The presence of syringotropism and folliculotropism indicates the need for more... (Source: Skin and Allergy News)
Source: Skin and Allergy News - April 22, 2015 Category: Dermatology Tags: SAN Conference News SAN Clinical News SAN News American Academy of Dermatology Source Type: news

Cutaneous T-Cell Lymphoma Therapeutic Development and Pipeline Market...
RnRMarketResearch.com adds “Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015” to its store. The report provides an overview of the Cutaneous T-Cell Lymphoma’s therapeutic pipeline.(PRWeb April 07, 2015)Read the full story at http://www.prweb.com/releases/cutaneous-t-cell-lymphoma/pipeline-review-h1-2015/prweb12636381.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 7, 2015 Category: Pharmaceuticals Source Type: news

FDA Approves Poteligeo for Rare Types of Non - Hodgkin Lymphoma
Drug approved to treat relapsed or refractory mycosis fungoides and Sézary syndrome (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Institutional, Source Type: news

Mycosis Fungoides and Leiomyosarcoma – Cancer Therapeutic Drugs and...
RnRMarketResearch.com adds “Mycosis Fungoides and Leiomyosarcoma – Pipeline Review, H2 2014” to its store. The report provides an overview of the Mycosis Fungoides and Leiomyosarcoma therapeutic...(PRWeb October 31, 2014)Read the full story at http://www.prweb.com/releases/2014-h2-retinoblastoma/leiomyosarcoma-pipeline/prweb12293087.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 1, 2014 Category: Pharmaceuticals Source Type: news

Response to Alemtuzumab for Leukemic Cutaneous T-Cell LymphomaResponse to Alemtuzumab for Leukemic Cutaneous T-Cell Lymphoma
Patients with leukemic cutaneous T-cell lymphoma (CTCL) who have diffuse erythema are more likely to experience complete response to alemtuzumab therapy, according to results from a small series. Reuters Health Information (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - May 2, 2014 Category: Dermatology Tags: Hematology-Oncology News Source Type: news

Novel Drug Shows Promise in T-Cell Lymphoma
DENVER (MedPage Today) -- An investigational drug, resiquimod, successfully healed cutaneous T-cell lymphoma lesions in a small peer-supported trial, researchers reported here. (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - March 24, 2014 Category: Dermatology Source Type: news

Should You Use Your Hand to Score Skin in CTCL?Should You Use Your Hand to Score Skin in CTCL?
Learn about a new iPhone app that can help with BSA assessment in CTCL. The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 6, 2013 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

First Proprietary Gel Product for Cutaneous Lymphoma First Proprietary Gel Product for Cutaneous Lymphoma
Although topical mechlorethamine (nitrogen mustard) has been used for decades in cutaneous T-cell lymphoma, only now is the product launched. FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 27, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
WOODCLIFF LAKE, N.J., Aug. 8, 2013 -- (Healthcare Sales & Marketing Network) -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational compound (E7777) for cutaneous t-cell ly... Biopharmaceuticals, Oncology, FDAEisai, orphan drug, E7777, cutaneous t-cell lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 8, 2013 Category: Pharmaceuticals Source Type: news

Skin Infections With Electron Beam Therapy for Mycosis...Skin Infections With Electron Beam Therapy for Mycosis...
There is a significant risk of cutaneous infection during total skin electron beam therapy (TSEBT) for mycosis fungoides, according to a new case series. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 26, 2013 Category: Consumer Health News Tags: Dermatology News Source Type: news